Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed

Updated 04/26/2024

Status Recruiting

Clinical Trial Summary

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05740566
Study type	Interventional
Source	Amgen
Contact	Amgen Call Center
Phone	866-572-6436
Email	medinfo@amgen.com
Status	Recruiting
Phase	Phase 3
Start date	May 31, 2023
Completion date	August 1, 2027

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05652686` - A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)	Phase 1
	Recruiting	`NCT05027100` - Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC	N/A
	Active, not recruiting	`NCT03708328` - A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Phase 1
	Recruiting	`NCT05158491` - Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC	Phase 1/Phase 2
	Completed	`NCT04285866` - Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
	Completed	`NCT03066778` - A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)	Phase 3
	Not yet recruiting	`NCT04727853` - Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)	Phase 2
	Withdrawn	`NCT02030184` - Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas	Phase 1/Phase 2
	Completed	`NCT03538028` - A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies	Phase 1
	Withdrawn	`NCT01210131` - Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)	N/A
	Terminated	`NCT01904253` - A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy	Phase 2
	Terminated	`NCT02934503` - Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)	Phase 2
	Completed	`NCT02580994` - Pembrolizumab in Untreated Extensive SCLC	Phase 2
	Completed	`NCT03811652` - A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors	Phase 1
	Recruiting	`NCT02628067` - Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Phase 2
	Active, not recruiting	`NCT02769832` - Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer	Phase 2
	Completed	`NCT02069158` - Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor	Phase 1
	Recruiting	`NCT03460977` - PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma	Phase 1